 MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 GLOBE NEWSWIRE -- Adicet Bio, Inc. Adicet Nasdaq: ACET, a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the closing of an underwritten public offering of 10,575,513 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock at a public offering price of 13.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses were approximately 137.5 million. All of the shares in the offering are to be sold by Adicet. 